Company Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel.
The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 5, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,826 |
| CEO | Ying Huang |
Contact Details
Address: 2101 Cottontail Lane Somerset, New Jersey 08873 United States | |
| Phone | 732 317 5050 |
| Website | legendbiotech.com |
Stock Details
| Ticker Symbol | LEGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001801198 |
| CUSIP Number | 52490G102 |
| ISIN Number | US52490G1022 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ying Huang Ph.D. | Chief Executive Officer and Director |
| Jessie Yeung M.B.A. | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Doug Wallace | Vice President of Global Operations |
| Dr. Guowei Fang Ph.D. | Chief Scientific Officer and Head of Business Development |
| Joanne Choi | Senior Manager of Investor Relations |
| James Pepin J.D. | General Counsel |
| Tim Roberts | Global Compliance Officer |
| Deborah Wong | Executive Director of Strategic Marketing and Corporate Communications |
| Elaine Qian | Vice President and Global Head of Human Resources |
| Dr. Yuhong Qiu Ph.D. | Senior Vice President of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 6-K | Report of foreign issuer |
| Jan 10, 2025 | 144 | Filing |
| Dec 26, 2024 | 144 | Filing |
| Dec 26, 2024 | 144 | Filing |
| Dec 23, 2024 | 6-K | Report of foreign issuer |
| Dec 10, 2024 | 6-K | Report of foreign issuer |
| Dec 2, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |